ENJAYMO MOA
Mechanism of Action

Inhibits hemolysis in
patients with CAD through
inhibition of the classical
complement pathway

Clipboard
Clinical Experience

Efficacy and safety
assessed in
CARDINAL trial

ENJAYMO dosing
Dosing AND STORAGE

Starting and continuing with ENJAYMO

ENJAYMO representative contact
LEARN MORE ABOUT ENJAYMO
FIND OUT HOW

IMPORTANT SAFETY INFORMATION
AND INDICATION

CONTRAINDICATIONS

ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients.

WARNINGS AND PRECAUTIONS

Serious Infections

Infusion-Related Reactions

Risk of Autoimmune Disease

Recurrent Hemolysis After ENJAYMO Discontinuation

ADVERSE REACTIONS

INDICATION

ENJAYMO (sutimlimab-jome) is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).

CAD=Cold Agglutinin Disease.

Reference: 1. ENJAYMO. Prescribing information. Genzyme Corporation.

IMPORTANT SAFETY INFORMATION
AND INDICATION

CONTRAINDICATIONS

ENJAYMO is contraindicated in patients with known hypersensitivity to sutimlimab-jome or any of the inactive ingredients.